GHRH Peptide Analog Protected Rat Retinas from Diabetic Damage Through Anti-Inflammatory and Antioxidant Effects

In streptozotocin-induced diabetic rats, treatment with the GHRH agonist MR-409 (15 μg/kg) prevented retinal morphological damage and particularly preserved retinal ganglion cell survival. MR-409 upregulated NRF-2-dependent antioxidant gene expression, downregulated pro-inflammatory cytokines and adhesion molecules, reduced VEGF expression while increasing PEDF expression, and decreased vascular permeability. GHRH and GHRH-R expression were significantly downregulated in both diabetic rat retinas and human diabetic retinas (postmortem). Treatment with the GHRH antagonist MIA-602 worsened retinal morphology, confirming that GHRH signaling is neuroprotective.

Researchers used streptozotocin-induced diabetic rats treated with the GHRH agonist MR-409 (15 μg/kg) or antagonist MIA-602. Retinal morphology was assessed histologically. Gene and protein expression were measured using qPCR and Western blotting for GHRH-R, inflammatory markers, oxidative stress pathways (NRF-2), and angiogenic factors (VEGF, PEDF). Vascular permeability was quantified. Human diabetic retinas (postmortem) were also analyzed for GHRH-R expression.

Current treatments for diabetic retinopathy (laser therapy, anti-VEGF injections) address late-stage disease. GHRH agonists could offer a new approach targeting early disease by simultaneously protecting neurons, reducing inflammation, fighting oxidative stress, and preventing vascular damage — addressing multiple pathological mechanisms with a single peptide-based therapy.

GHRH is primarily known for stimulating growth hormone release, but this study reveals a direct tissue-protective role in the retina independent of growth hormone. This adds to growing evidence that GHRH analogs have therapeutic potential beyond endocrinology — in conditions involving inflammation, oxidative stress, and neurovascular injury. The finding that GHRH-R is downregulated in human diabetic retinas validates the translational relevance of this work.

This is a preclinical study in diabetic rats, and results may not directly translate to human diabetic retinopathy. The streptozotocin model mimics type 1 diabetes, while most diabetic retinopathy occurs in type 2 diabetes. The study examined early-stage retinopathy and did not assess whether MR-409 can reverse established disease. Long-term safety data for retinal use of GHRH agonists is lacking.